Liverpool COVID-19 Drug Interactions (www.covid19-druginteractions.org)

利物浦大学药物互动集团在开发传染病方面的处方支持资源方面拥有20多年的经验，我们世界著名的艾滋病毒和肝炎药物互动网站(www.hiv-Pharmginteractions.org和www.hep-Pharmginteractions.org)和相关应用程序证明了这一点。2019年，这些网站每月有超过5万名独立访问者在搜索&gt；450万次互动。我们的网站在30多个国际治疗指南和许多国家指南中得到推荐。为了应对新冠肺炎大流行，并解决正在使用新冠肺炎试验性疗法的研究和临床情况下对处方支持的迫切需求，我们开发了一个静态药物相互作用网站(www.covid19-Pharmginteractions.org)，提供有关实验制剂和常用处方联合药物之间相互作用可能性的信息。我们现在必须采取行动，开发一个完全互动和可搜索的网站资源与相关的应用程序。该网站将不断更新和填充关于实验疗法的最新信息，并为临床医生提供管理复杂患者的指导。

The Liverpool University Drug Interactions group has over twenty years' experience in developing prescribing support resources in infectious diseases, demonstrated by our world-renowned HIV and Hepatitis drug interaction websites (www.hiv-druginteractions.org and www.hep-druginteractions.org) and associated Apps. In 2019, these websites had over 50,000 unique monthly visitors searching for >4.5 million interactions. Our websites are recommended in over 30 international treatment guidelines and many national guidelines. In response to the COVID-19 pandemic and to address the pressing need for prescribing support for studies and clinical situations where experimental COVID-19 therapies are being used, we have developed a static drug interactions website (www.covid19-druginteractions.org) providing information on the likelihood of interactions between the experimental agents and commonly prescribed co-medications. We now have to move to develop a fully interactive and searchable website resource with an associated App. The website will be constantly updated and populated with the latest information on experimental therapies with guidance given to clinicians for managing complex patients.